Trading on the Nasdaq as BIOC, US-based Biocept raised $19m to be added to the $15.9 million already generated through seed and series funding. Investors include Needham Capital Partners who invest in the biotech and life science industries.
Biocept provides products and services to detect and analyse rare cells in order to provide information that physicians can use to make treatment decisions.
Aegis Capital Corporation and Feltl and Company acted as joint book-running managers for the offering. Biocept has also granted a 45-day option to purchase up to 285,000 additional shares of common stock to the underwriters to cover any overallotments.